Institutional members access full text with Ovid®

A New Monoclonal Antibody for Ulcerative Colitis and Crohn's Disease

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: September 2014 - Volume 114 - Issue 9 - p 25
doi: 10.1097/01.NAJ.0000453754.39012.e7
Drug Watch

* Vedolizumab (Entyvio) is a newly approved treatment for adults with moderate-to-severe ulcerative colitis or moderate-to-severe Crohn's disease when standard therapies haven't been successful.

* The most common adverse effects are nasopharyngitis, headache, joint pain, nausea, and fever. Vedolizumab can also produce hypersensitivity (anaphylactic) and infusion-related reactions, hepatotoxicity, and progressive multifocal leukoencephalopathy.

© 2014 Lippincott Williams & Wilkins. All rights reserved.